# PDUFA dates February 2028: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2028-02

> 33 FDA catalysts are dated in February 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in February 2028

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 2028 | [QMF149 primary completion](https://sec-api.dev/pdufa/qmf149) | NVS | Asthma | scheduled | "NCT05562466 (A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05562466)) |
| February 2028 | [Dato-dxd primary completion](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | scheduled | "NCT07205822 (A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07205822)) |
| February 2028 | [PF-08049820 primary completion](https://sec-api.dev/pdufa/pf-08049820) | PFE | Atopic Dermatitis; Eczema, Atopic | scheduled | "NCT07216027 (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216027)) |
| February 2028 | [Rsvpref vaccine primary completion](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07768345 (A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768345)) |
| February 2028 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Atherosclerotic Cardiovascular Disease (ASCVD) | scheduled | "NCT06813911 (Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06813911)) |
| February 2028 | [RAP-219 primary completion](https://sec-api.dev/pdufa/rap-219) | RAPP | Focal Epilepsy; Epilepsy; Refractory Focal Epilepsy | scheduled | "NCT07219407 (A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-03 (ESTIMATED); Lead Sponsor Rapport Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219407)) |
| February 2028 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223138)) |
| February 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Severe Asthma | scheduled | "NCT07363642 (Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363642)) |
| February 2028 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension | scheduled | "NCT07686120 (A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686120)) |
| February 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Microvascular Inflammation | scheduled | "NCT07219043 (A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-10 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219043)) |
| February 2028 | [Decitabine primary completion](https://sec-api.dev/pdufa/decitabine) | NVS | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic | scheduled | "NCT05201066 (Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05201066)) |
| February 2028 | [Rapcabtagene autoleucel primary completion](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT06581198 (A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581198)) |
| February 2028 | [JNJ-101556143 primary completion](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07906717 (A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07906717)) |
| February 2028 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Solid Tumors | scheduled | "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415031)) |
| February 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight and/or Obesity; Overweight | scheduled | "NCT07845500 (A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07845500)) |
| February 2028 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) | scheduled | "NCT06512883 (A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06512883)) |
| February 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease; Psychosis | scheduled | "NCT06947941 (A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-21 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947941)) |
| February 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Overweight; Obesity | scheduled | "NCT07770841 (Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-22 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07770841)) |
| February 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity; Type 2 Diabetes | scheduled | "NCT07564414 (A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07564414)) |
| February 2028 | [Baxdrostat/dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT06268873 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268873)) |
| February 2028 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | RSV Infection | scheduled | "NCT06866405 (A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06866405)) |
| February 2028 | [Remibrutinib (blinded) primary completion](https://sec-api.dev/pdufa/remibrutinib-blinded) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06744920 (A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744920)) |
| February 2028 | [REGN13335 primary completion](https://sec-api.dev/pdufa/regn13335) | REGN | Pulmonary Arterial Hypertension (PAH) | scheduled | "NCT07318597 (Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-27 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07318597)) |
| February 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis | scheduled | "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05037760)) |
| February 2028 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | scheduled | "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05816382)) |
| February 2028 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855498)) |
| February 2028 | [Mmrvns primary completion](https://sec-api.dev/pdufa/mmrvns) | GSK | Measles; Measles-Mumps-Rubella+Chickenpox Vaccine | scheduled | "NCT07406360 (A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07406360)) |
| February 2028 | [Remestemcel-l-rknd primary completion](https://sec-api.dev/pdufa/remestemcel-l-rknd) | MESO | GVHD - Graft-Versus-Host Disease | scheduled | "NCT07568535 (A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Mesoblast, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07568535)) |
| February 2028 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | scheduled | "NCT07733180 (A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733180)) |
| February 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091254)) |
| February 2028 | [NNC6019-0001 primary completion](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT06260709 (A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260709)) |
| February 2028 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Neoplasms, Endometrial | scheduled | "NCT07286331 (A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286331)) |
| February 2028 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Meningioma | scheduled | "NCT07428616 (A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07428616)) |

Other months: https://sec-api.dev/fda-calendar/2028-01 , https://sec-api.dev/fda-calendar/2028-03. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates February 2028: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2028-02

```bibtex
@misc{secapidev_fda_calendar_2028_02_20261116,
  title        = {PDUFA dates February 2028: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2028-02}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2028_02_20261116","title":"PDUFA dates February 2028: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2028-02","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
